The American Society of Clinical Oncology (ASCO) hosts an annual meeting every spring. At this meeting, oncologists, physicians, researchers, industry members, advocacy organizations (like GO2,) patients, and caregivers come together to share and learn about the latest and most [...]
Question: I am interested in learning more about clinical trials as a treatment option for my lung cancer. How do I know if I am eligible? How can I find a clinical trial that is a good fit for [...]
GO2 for Lung Cancer Chief Patient Officer Danielle Hicks has been on the front lines confronting lung cancer for very personal reasons. With a family history of lung cancer spanning 3 generations, she is helping unlock the origins of [...]
On June 13, 2024, the U.S. Food and Drug Administration (FDA) granted accelerated approval of Augtyro (repotrectinib) for adults and children aged 12 years and older with NTRK-positive solid tumors, including non-small cell lung cancer (NSCLC). The new approval [...]
Contributing Authors: Brittney Nichols, MPH, RN-BSN, Senior Specialist, Science and Research, GO2 for Lung Cancer; Andrew Ciupek, PhD, Associate Director, Clinical Research, GO2 for Lung Cancer; and Renee Botello, MSc, Navigator, Treatment and Trials, GO2 for Lung Cancer Every [...]
Authors: Matthew Reiss, MSE, PhD, Manager, Precision Medicine & Navigation, GO2 for Lung Cancer and Courtney Granville, PhD, MSPH, Chief Scientific Officer, GO2 for Lung Cancer Earlier this year, GO2 for Lung Cancer welcomed Courtney Granville, PhD, MSPH, as [...]
Authors: Andrew Ciupek, PhD, Associate Director, Clinical Research, GO2 for Lung Cancer and Brittney Nichols, MPH, BSN-RN, Senior Specialist, Science and Research, GO2 for Lung Cancer Blood-based testing has become increasingly common in cancer care. In addition to routine [...]
Author: Andrew Ciupek, PhD, Associate Director, Clinical Research, GO2 for Lung Cancer Although most lung cancer cases happen at an older age and are associated with a history of smoking, a growing number of people are diagnosed who do [...]
Author: Renee Botello, MSc, Navigator, Treatment and Trials, GO2 for Lung Cancer Over the years, efforts to prevent lung cancer and teach the public about its link to smoking have resulted in negative and sometimes false viewpoints about the [...]
On May 16, 2024, the U.S. Food and Drug Administration (FDA) granted Imdelltra (tarlatamab-dlle) accelerated approval for people with extensive stage small cell lung cancer (ES-SCLC) following progression on or after platinum-based chemotherapy. The approval is based on results [...]